Japan’s Takeda Sees Largest Earnings Gain In Six-Plus Years
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical registered its biggest stock market gain in six years after an analyst noted the Japanese firm was experiencing steady earnings. The Nikko Citigroup analyst also noted, however, that Takeda still does not have a successor for its Actos (pioglitazone hydrochloride) diabetes drug, whose patent is set to expire in 2011. He said Takeda is looking to its SYR-322 (alogliptin) type 2 diabetes drug and a joint-venture stomach ulcer drug to counter the expected decline in Actos sales, and has ample cash for mergers and acquisitions. (Click here for more